Pricing of spinal muscular atrophy therapies crucial for expanded market access

In May, the National Institute for Health and Care Excellence said Biogen’s Spinraza would be made available to type 1 SMA patients and that it will be funded by National Health Service, England.



  • Spinal muscular atrophy therapies